NowenIgGenix
UnclaimedIgGenix is a clinical-stage biotech company developing antibody therapies to treat allergies.
Overview
IgGenix is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapies to treat allergies. Led by experienced biotech leaders, the company seeks to translate scientific research into transformative treatments that improve the health and well-being of individuals affected by allergic conditions. IgGenix emphasizes scientific rigor, collaboration, and patient impact as it advances its internal programs through clinical development.
Mission statement
IgGenix's mission is to develop transformational antibody therapies that improve the health and quality of life for people living with allergies.
Work at IgGenix? Decide what AI assistants read about you.
Claim IgGenixUse your email at derekcroote.com.What we offer
IGNX001
Transformative antibody therapeutic for peanut allergy, completed Phase 1 trial.
iggenix.com →Market segments
Market size by segment
Growth potential (CAGR)
Peanut allergy therapeutics
Therapies specifically designed to prevent or reduce allergic reactions to peanuts, including monoclonal antibodies and targeted immunotherapies aimed at desensitization and protection from anaphylaxis.
Products: IGNX001
Clinical-stage antibody therapeutics
Monoclonal antibody candidates undergoing clinical development for immune-mediated conditions, with emphasis on clinical safety, efficacy, and advancement through Phase 1–3 trials.
Products: IGNX001
Biopharmaceutical partnering and licensing
Opportunities for licensing, co-development, and strategic partnerships around clinical-stage biologic assets to accelerate development, manufacturing, and commercialization.
Products: IGNX001
More information about our offering
IGNX001
IGNX001 is IgGenix's internally developed antibody therapeutic for peanut allergy. It is designed to provide a transformative solution for individuals suffering from this condition and completed a Phase 1 clinical trial in November 2025.
- Achieved Phase 1 Clinical TrialSuccessfully completed initial human trials, demonstrating its potential efficacy and safety for treating peanut allergies.
Sources
Methodology and sourcing behind the figures and links shown above.
Peanut allergy therapeutics
Estimate anchored to market-research figures for the peanut-allergy vaccine/therapeutics segment: Coherent Market Insights reports a peanut allergy vaccine market of USD 1.15B in 2026 with a 16.9% CAGR (2026–2033). That vaccine/immunotherapy-focused projection is corroborated by a LinkedIn-sourced market note (~USD 1.2B in 2026; ~15.5% CAGR) and a MeditechInsights statement of ~12% near-term growth for the broader peanut allergy treatment market. SphericalInsights shows the broader allergy therapeutics market at USD 23.1B (2023), indicating peanut-specific therapeutics are a smaller, rapidly growing subsegment driven by immunotherapies and biologics.
- Global Peanut Allergy Vaccine Market size is estimated at USD 1.15 billion in 2026; CAGR of 16.9% from 2026 to 2033.
- Global Peanut Allergy Therapeutics market valued at USD 1.2 Billion in 2026; CAGR ~15.5% (2026–2033).
- The global peanut allergy treatment market size is set to witness a growth rate of 12% in the next 5 years.
- Global Allergy Therapeutics Market size was valued at USD 23.1 Billion in 2023; CAGR 6.29% (2023–2033).
Clinical-stage antibody therapeutics
Used published market forecasts for the broader antibody/monoclonal antibody therapeutics market as the addressable market for clinical‑stage antibody candidates. Primary proxy is MarketsandMarkets (USD 311.2B in 2026; 7.5% CAGR). Other sources show a range (Coherent ~USD 331.8B in 2026, BioSpace USD 233.2B in 2024, PrecedenceResearch USD 973.6B in 2024), so a conservative CAGR (7.5%) and the MarketsandMarkets 2026 market size were used as the baseline for clinical‑stage antibody therapeutics’ near‑term market potential.
Biopharmaceutical partnering and licensing
Estimate based on the overall biopharmaceutical market scale and growth (persistence market research), observed annual licensing revenues from academia (NCBI/PMC) and representative deal economics (PharmExec). Using the $515.8B biopharma market (2025) as context and university licensing revenue (~$6B) plus frequent multi‑million upfronts and multi‑hundred‑million-to‑billion milestone structures in industry deals, partnering and licensing of clinical‑stage biologics is estimated as a multi‑billion annual market (approx. 2–3% of total biopharma market). Growth potential is aligned with the broader biopharma CAGR (8–10%), reflecting increasing strategic collaborations and biologics dealmaking.
- The global biopharmaceutical market size is valued at US$515.8 billion in 2025 and projected to reach US$910.7 billion; CAGR 8.5%.
- Combined revenues from licensing and industry-supported research in all fields reaching well over $6 billion per year (AUTM 2012).
- Manifold Bio will receive an upfront fee of $55 million and eligibility for milestones valued upwards of $2 billion.
- IgGenix
- IGNX001
- Global Peanut Allergy Vaccine Market size is estimated at USD 1.15 billion in 2026; CAGR of 16.9% from 2026 to 2033.
- Global Peanut Allergy Therapeutics market valued at USD 1.2 Billion in 2026; CAGR ~15.5% (2026–2033).
- The global peanut allergy treatment market size is set to witness a growth rate of 12% in the next 5 years.
- Global Allergy Therapeutics Market size was valued at USD 23.1 Billion in 2023; CAGR 6.29% (2023–2033).
- $311.2B MARKET SIZE, 2026; CAGR (2026-2035): 7.5%
- valued at USD 331.81 Bn in 2026; CAGR of 12.9% (2026–2033)
- USD 233.19 billion in 2024; CAGR of 14.7% between 2024 and 2033
- valued at USD 973.6 billion in 2024; CAGR of 12% through 2034
- The global biopharmaceutical market size is valued at US$515.8 billion in 2025 and projected to reach US$910.7 billion; CAGR 8.5%.
- Combined revenues from licensing and industry-supported research in all fields reaching well over $6 billion per year (AUTM 2012).
- Manifold Bio will receive an upfront fee of $55 million and eligibility for milestones valued upwards of $2 billion.
This is a public preview. Whoever claims it decides what it shows.
This profile was built from public information. Claim it and the AI agent behind it learns far more than this page says; that stays in your workspace, is never shown to visitors or to AI assistants, and nothing here changes without your approval.
Own this company? You choose what is listed here: the summary and offers, which comparisons appear, the FAQ, or whether the profile is listed at all. Unlisting takes one switch.
Built from public web sources. Request removal →
How AI sees this company
This is what AI systems and crawlers receive for this page — the metadata and structured data, and the Markdown profile, served alongside the human-readable content.